Celltelligence’s Post

View organization page for Celltelligence, graphic

582 followers

On Friday, March 15, Johnson & Johnson (press release: https://bit.ly/4a3GR86) and Legend Biotech (press release: https://bit.ly/43qvAfK) announced that the FDA’s Oncologic Drugs Advisory Committee (ODAC) recommended #Carvykti (#BCMA CAR-T) for the treatment of adult patients with r/r #MM who have received at least one prior LoT including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD) and are refractory to lenalidomide. On the same day, Bristol Myers Squibb (press release: https://bit.ly/3TrG61B) and 2seventy bio (press release: https://bit.ly/4a2aLd0) reported that the FDA’s ODAC also recommended #Abecma (BCMA CAR-T) for the treatment of patients with triple-class exposed (#TCE) r/r MM. Celltelligence provides insights on the FDA efficacy and safety concerns on the two BCMA CAR-Ts, while discussing the outcomes of the #ODAC meeting: https://bit.ly/CT-864684

  • No alternative text description for this image

To view or add a comment, sign in

Explore topics